Aurinia Pharmaceuticals
AUPH
145 hedge funds and large institutions have $948M invested in Aurinia Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 68 increasing their positions, 29 reducing their positions, and 19 closing their positions.
134% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 29
68% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 19
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
23% more call options, than puts
Call options by funds: $38M | Put options by funds: $30.8M
10% more funds holding
Funds holding: 132 → 145 (+13)
0.81% less ownership
Funds ownership: 52.28% → 51.47% (-0.81%)
1% less capital invested
Capital invested by funds: $956M → $948M (-$8.62M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$51.5M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$37.4M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$36M |
| 4 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$23.2M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$15.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$75.1M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
-$27.1M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$21.7M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$16.4M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$15.7M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MS
151
Maven Securities
St Helier,
Jersey
| – | -$813K | -50,000 | Closed |
|
|
BFM
152
Boothbay Fund Management
New York
| – | -$579K | -35,638 | Closed |
|
|
LCM
153
Laurion Capital Management
New York
| – | -$523K | -32,211 | Closed |
|
|
MWNA
154
Marshall Wace North America
New York
| – | -$489K | -30,200 | Closed |
|
155
Marshall Wace
London,
United Kingdom
| – | -$303K | -18,740 | Closed |
|
156
Walleye Trading
New York
| – | -$219K | -13,487 | Closed |
|
|
TI
157
tru Independence
Portland,
Oregon
| – | -$145 | -8,900 | Closed |
|
158
Skandinaviska Enskilda Banken (SEB)
Stockholm,
Sweden
| – | -$75K | -4,600 | Closed |
|
|
KPW
159
Kore Private Wealth
New York
| – | -$32K | -2,000 | Closed |
|
|
LC
160
Lindbrook Capital
Calabasas,
California
| – | -$24K | -1,500 | Closed |
|
|
CAN
161
Cetera Advisor Networks
El Segundo,
California
| – | -$15K | -920 | Closed |
|
|
PAG
162
Private Advisor Group
Morristown,
New Jersey
| – | -$14K | -850 | Closed |
|
|
LWM
163
Liberty Wealth Management
Oakland,
California
| – | -$2K | -120 | Closed |
|
AUPH Hedge Fund Activity: Q3 2020 in Review
145 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Aurinia Pharmaceuticals (AUPH) for Q3 2020, worth a combined $948M — down 0.9% from $956M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new AUPH positions and 19 closed out — a net gain of 13 holders — while 68 added to existing stakes and 29 trimmed.
The largest buyer was OrbiMed, adding an estimated $51.5M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $75.1M sold.
- 145 institutional investors held Aurinia Pharmaceuticals (AUPH) as of Q3 2020, up from 132 in Q2 2020.
- Funds reported $948M of Aurinia Pharmaceuticals stock for Q3 2020, down 0.9% quarter-over-quarter.
- 32 funds opened new Aurinia Pharmaceuticals positions in Q3 2020 and 19 closed out, a net change of +13 holders.
- The largest Aurinia Pharmaceuticals buyer in Q3 2020 was OrbiMed, an estimated $51.5M added.
- The largest Aurinia Pharmaceuticals seller in Q3 2020 was Consonance Capital Management, an estimated $75.1M sold.
Based on aggregated 13F filings for Q3 2020.